NeuroPace's 20% Story Meets a 1% Quarter
A growth medtech blames account concentration and its own reorg for a revenue stall — while the real catalyst (IGE) sits nine months away and the cash position is already net negative
NPCE · Earnings Call · 2026-11-12
A broken say-do ratio
NeuroPace spent five quarters telling investors the adult focal business could compound at 20%+ and that it would only accelerate from there. In the third quarter of 2026, RNS System revenue grew 1.4%, to $22.9 million, and total revenue actually declined 1.1% to $23.1 million. Full-year guidance went from $99.5–101.5 million to $91–92 million. The stock has given up 55.8% over the past 90 trading days, with roughly 42% of that in the final four sessions — the market did not need to think about it. The remarkable thing is how recent the confidence was. In August, the CFO explained away a second-half step-up question like this: “What gives us confidence in the second half is what we've done historically. If you go back in time and look at even second half of last year, we grew 32% year-over-year... History and obviously visibility in the business that we have now gives us that confidence.” — Patrick Williams, Chief Financial Officer · 2026-08-11 In May he had raised guidance above the beat — “raise guidance on top of that above the beat” — Patrick F. Williams, Chief Financial Officer · 2026-05-12 — with a straight face and an all-time-high prescriber count behind it. Two quarters later: “Our third quarter results fell short of our expectations, and I want to be direct about why and also what we're doing about it.” — Joel Becker, Chief Executive Officer · 2026-11-12 The CFO named the cost of that: “Ultimately, we have to perform and get back to that high say-do ratio as we like to say.” — Patrick Williams, Chief Financial Officer · 2026-11-12 That is the sentence that matters. Small-cap medtech is valued off credibility on the growth curve, and the curve just broke.Three excuses that are really one problem
The keyword register flipped violently this quarter. large accounts shot to the top of the company's own list, and customer concentration entered the agenda for the first time — neither was a top-30 theme at any point in the prior twelve quarters. Management laid out three causes: local operational disruption at a handful of big centers (staffing, physician availability, diagnostic capacity), a mid-year sales leadership and field-clinical restructuring, and the delayed operational consequence of exiting the SEEG distribution business. That third one is the most interesting reversal. For over a year, DIXI/SEEG was framed as low-value revenue being shed to free up rep time. Today it is a demand headwind: “A nuance was the picking up or not of cases as a result of being there on a more ongoing basis... we don't need to be in the SEEG business.” — Joel Becker, Chief Executive Officer · 2026-11-12 The SEEG business exit gave back operating-room presence at exactly the accounts that matter most. That is a strategic-own-goal framing whether or not management will call it one. The explanation is also self-undermining in an instructive way. The CEO argued the shortfall is concentrated: “With a customer concentration like we have, any disruption in those larger accounts has an outsized effect.” — Joel Becker, Chief Executive Officer · 2026-11-12 True — but the same call reveals the fix is a bigger, more expensive field force, with quota-carrying reps added in 2027. Meanwhile 2026 adjusted opex guidance was cut to $85–86 million from $90–92 million, largely on lower sales commissions and variable comp. You do not cut the commission line in the year you promise to fix coverage. The spending step-up lands after the comp base resets — read that as you will. The one genuinely new competitive question came from Wolfe's Michael Polark: whether VNS's step-change in reimbursement economics is peeling off cases in overlapping subsegments. The CEO's answer was carefully hedged — “We don't hear where we are losing competitive market share head-to-head based on that reimbursement change.” — Joel Becker, Chief Executive Officer · 2026-11-12 Note that the same analyst asked about vagus-nerve APC repricing two quarters ago and management then treated it as broadly constructive for neuromodulation. It is now a question to be deflected. That is a site of service economics story, not a device-technology one.Catalysts intact — but the wrong calendar
What has not changed is the regulatory timeline, and it is slow. The IGE PMA supplement amendment goes in around year-end, SIR meeting feedback is being incorporated, and the company now plans for the full 180-day clock, pointing to approval around mid-2027. Remote Care, submitted ahead of schedule, is another mid-2027 event. AURORA, the retrospective adolescent study, enrolls through early 2027 with submission during the year and approval late 2027 or early 2028. The IGE indication expansion opportunity is real and large — roughly 70,000 adolescent focal patients and $3.5 billion of addressable market per management — but none of it shows up before the second half of 2027, and guidance explicitly excludes every dollar of it. That leaves 2027 as a self-funded bridge: H1 growth of 10–15%, H2 of 15–20%, full year ~15%. Which is another way of saying the 20% base case has been pushed out at least a year on the core indication alone. Balance sheet scrutiny matters here. The last filed quarter (June, before this print) showed revenue of $23 million with a six-year trend of +148%, gross margin of 82.8%, and an operating margin of -22.5%. Free cash flow margin was -27.7%, R&D intensity a still-heavy ~30% of revenue, and effective net cash has swung negative to -$7M. At $49.5 million of cash against $59.2 million of long-term borrowings, plus a guided full-year adjusted EBITDA loss of $8.5–9.5 million, this is not a company that can afford many more quarters like this one. The multiple — 5.5x revenue — is still a growth multiple attached to a non-growth print.The trade
The bull case now rests on a single proposition: that this was execution, not demand. The tell is whether commercial execution — which management insists is already fixed structurally — shows up as accelerating Q4 procedure volumes and a clean first half of 2027. The bear case is that a company with high account concentration, a hobbled field organization, and a competitor enjoying a reimbursement windfall has simply met its ceiling in adult focal, and that the IGE catalyst is too far away to hold a de-rated multiple. Either way, the accountability line was unusually blunt for a device CEO:The market has already rendered a verdict of sorts — down more than half from July's high — and the next real datapoint is not a press release, it is Q4 procedure cadence. Until then, the story is a company asking to be believed twice.I am accountable for and I take very seriously the disappointing revenue results here in Q3. I think about our owners and the people who follow NeuroPace every day.